The biology and treatment of EML4-ALK non-small cell lung cancer

详细信息    查看全文

• 作者：Takaaki Sasaki ; Scott J. Rodig ; Lucian R. Chirieac ; Pasi A. Jä ; nne
• 关键词：Non-small cell lung carcinoma ; Translocation ; Kinase inhibitor ; Clinical trial
• 刊名：European Journal of Cancer
• 出版年：2010
• 出版时间：July 2010
• 年：2010
• 卷：46
• 期：10
• 页码：1773-1780
• 全文大小：670 K

文摘

The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.